"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
Descriptor ID |
D016219
|
MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 3 | 4 | 7 |
1995 | 7 | 2 | 9 |
1996 | 5 | 0 | 5 |
1997 | 4 | 2 | 6 |
1998 | 7 | 2 | 9 |
1999 | 2 | 1 | 3 |
2000 | 3 | 2 | 5 |
2001 | 8 | 3 | 11 |
2002 | 10 | 5 | 15 |
2003 | 6 | 8 | 14 |
2004 | 10 | 1 | 11 |
2005 | 7 | 1 | 8 |
2006 | 11 | 2 | 13 |
2007 | 8 | 2 | 10 |
2008 | 5 | 2 | 7 |
2009 | 6 | 3 | 9 |
2010 | 13 | 5 | 18 |
2011 | 20 | 2 | 22 |
2012 | 13 | 9 | 22 |
2013 | 9 | 7 | 16 |
2014 | 20 | 8 | 28 |
2015 | 16 | 2 | 18 |
2016 | 13 | 15 | 28 |
2017 | 21 | 8 | 29 |
2018 | 31 | 15 | 46 |
2019 | 31 | 10 | 41 |
2020 | 37 | 27 | 64 |
2021 | 51 | 25 | 76 |
2022 | 14 | 45 | 59 |
2023 | 17 | 56 | 73 |
2024 | 32 | 21 | 53 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies. Blood Adv. 2024 Aug 13; 8(15):4066-4076.
-
Approved CAR-T therapies have reproducible efficacy and safety in clinical practice. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2378543.
-
Human herpesvirus 6 reactivation and disease are infrequent in chimeric antigen receptor T-cell therapy recipients. Blood. 2024 Aug 01; 144(5):490-495.
-
Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy. Cancer Immunol Res. 2024 Aug 01; 12(8):1108-1122.
-
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors. J Immunother Cancer. 2024 Jul 22; 12(7).
-
Tumor-infiltrating lymphocytes: A new hope. Cancer Cell. 2024 Aug 12; 42(8):1315-1318.
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
-
Risk of T-cell malignancy after CAR T-cell therapy in children, adolescents, and young adults. Blood Adv. 2024 Jul 09; 8(13):3544-3548.
-
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024 Jul 08; 14(1):108.
-
The approval of lisocabtagene maraleucel in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2024 Jul-Aug; 22(6):291-293.